BEAM vs BBUC Comparison

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Brookfield Business Corp is the operator of vital industrial and business services operations. The company focuses on acquiring market businesses for value, execute its operational improvement plans to increase cash flows and recycle capital to compound long-term growth. Geographically, it derives maximum revenue from the United States, and the rest from Europe, Brazil, Australia, Canada, and others. It operates in four segments within particular sectors namely: business services, infrastructure services, industrials, and corporate. The company derives maximum revenue from Industrials segment engaged in energy storage operations, engineered components manufacturing operations, water and wastewater operations, electric heat tracing systems manufacturer, and other industrials operations.